43 results about "Treatment targets" patented technology

The present disclosure provides a radiotherapy plan generation method, comprising: obtaining object information of a target object, the object information comprising at least medical image information and a treatment target of the target object; calculating a field intensity distribution according to the object information, the field intensity distribution comprising a plurality of dose grids and beam information of a corresponding beam of each dose grid; selecting a target dose grid from each dose grid based on a difference between an actual dose of each dose grid and a target dose; constructing an inverse optimization problem according to each target dose grid; and solving the inverse optimization problem to generate a radiotherapy plan.

The application relates to the fields of medical diagnosis and gene drugs, and particularly relates to application of long-chain non-coding RNA in preparation of a heart insufficiency diagnosis reagent or kit. The application also provides application of the long-chain non-coding RNA in preparation of a heart insufficiency treatment drug. The application first finds that LOC107984012 is long-chain non-coding RNA which is highly expressed in a failing heart, and provides a new diagnosis marker and treatment target for heart insufficiency.

The application discloses a polypeptide GRN-E and application thereof in preparation of a medicine or preparation for perimenopausal emotional disorder. It is found for the first time that a GRN-E fragment (a C-terminal domain of PGRN, an amino acid sequence is SEQ ID NO. 1 in a sequence listing) can pass through a blood-brain barrier and has a unique effect in relieving perimenopausal anxiety and depression. As a key functional fragment, the GRN-E has a more concentrated effect on a central nervous system and can effectively avoid off-target effects of a full-length protein. The polypeptide GRN-E of the application can be applied to preparation of a medicine or preparation for perimenopausal emotional disorder as an innovative treatment target and a novel biological preparation and has a high clinical conversion value.

The control circuitry is able to access 400 patient-specific multidimensional information and subsequently, at least in part, automatically determine 406 supplementary boundaries for at least a portion of the patient (such as treatment targets and / or one or more organs at risk) based on the multidimensional information. The latter may include determining margins added to the boundaries of at least a portion of the patient. The control circuitry can then, for example, determine 407 the planned treatment volume based at least in part on the supplementary boundaries. These teachings will then allow for the optimization 408 of a patient-specific, radiotherapy-based treatment plan, for example, based on various motion dimensions derived at least in part from the aforementioned multidimensional information.

The application discloses application of CCL3-AS1 in regulating stability of carotid artery plaque, overexpression of CCL3-AS1 induces inflammatory activity of macrophages and secretion of MMP9, promotes plaque rupture and thrombosis; on the contrary, knockdown of CCL3-AS1 inhibits inflammatory activity of macrophages and secretion of MMP9, reduces plaque rupture and thrombosis; in addition, the application also discloses that CCL3-AS1 enhances MMP9 mRNA stability by combining with hnRNP-K, thereby increasing MMP9 expression and secretion and degrading fibrous cap collagen. The application discloses important role of CCL3-AS1 in stability of carotid artery plaque and a molecular mechanism, provides a new diagnostic marker and a treatment target, not only provides a new direction for research on atherosclerosis related diseases, but also provides a new tool and a means for clinical diagnosis and treatment.

The application discloses an evaluation system for an epilepsy electroacupuncture treatment target based on an amygdala nerve response prediction, relates to the technical field of nerve regulation and brain function modeling, and realizes the multi-modal synchronous collection of brain region potentials, blood oxygen and metabolic activities through high-density EEG, electrophysiological sensors, fMRI and PET, and constructs a standardized nerve response dataset and a brain region function mapping matrix. An amygdala prediction response index is calculated and compared with a response threshold, a stimulation response compliance judgment and parameter correction are realized. The nerve response propagation delay, cooperative coupling coefficient and epilepsy wave front tracing time are calculated, a comprehensive target evaluation coefficient is obtained, and effective target points are screened. Based on the treatment scheme implementation of the effective target point set, the nerve feedback data in the continuous treatment cycle is monitored in real time, and a nerve plasticity correction index is calculated, compared with a plasticity stability threshold, an adaptive feedback regulation closed loop is formed, and precise prediction and dynamic optimization control of epilepsy electroacupuncture targets are realized.

The application discloses application of NAMPT as a target point in preparation of a medicine for treating uveitis, wherein the medicine contains a NAMPT inhibitor, the NAMPT inhibitor is FK866, and the NAMPT inhibitor is used for inhibiting expression or activity of NAMPT, thereby down-regulating CD4 + The Hif1a expression level of T cells reestablishes the Teff / Treg balance, and inhibits occurrence and development of uveitis, thereby providing a brand-new drug target for treatment of uveitis. Meanwhile, the application verifies that the NAMPT-HIF1a axis has conservation and potential treatment value in uveitis through experiments, proves that NAMPT can become a potential treatment target of uveitis, and proposes that a NAMPT inhibitor is used for preparing the medicine for treating uveitis, thereby laying a solid theoretical and experimental foundation for development of a new generation of targeted medicine for treating uveitis.

A medical device is disclosed, which is capable of preventing a maintenance treatment element imparting energy to biological tissue from being displaced from a treatment target site and a treatment method performed on a heart failure patient. A medical device is disclosed, which includes a shaft portion, an expandable and contractible expansion body provided on a distal side of the shaft portion, and a maintenance treatment element disposed in the expansion body and imparting energy to biological tissue. The expansion body includes a concave portion recessed in a direction intersecting with an axial direction of the shaft portion. The maintenance treatment element is disposed in the concave portion.

This application relates to a method, system, device, and medium for intelligent prescription generation in primary healthcare, belonging to the technical field of medical auxiliary diagnosis. The method includes: real-time collection and analysis of doctor-patient dialogue content to extract diagnostic information, including chief complaint information, present illness history, allergy history, and past medical history; extraction of key pathophysiological parameters based on the diagnostic information; generation of current treatment information based on the key pathophysiological parameters and filling it into a medical record template, the current treatment information including a set of diagnoses for the current visit and a set of treatment goals for each diagnosis; generation of a personalized prescription suggestion draft based on the current treatment information, and formation of a formal prescription after review and confirmation by a doctor; and a qualification review of the formal prescription, and generation of a personalized medication guidance sheet after approval. This application has the beneficial effect of alleviating the workload of primary healthcare doctors and improving prescription quality.

A renal failure blood therapy system includes a memory device storing a therapy target for a patient. The system also includes a processor configured to receive the therapy target for the patient, receive a desired solute concentration for the patient, and apply the therapy target and the desired solute concentration as inputs to an optimization routine. The processor is also configured to execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate or a dialysis therapy dialysate flow rate. The processor is further configured to display the at least one dialysis therapy prescription for confirmation or selection by a clinician and transmit the selected or confirmed dialysis therapy prescription to a dialysis machine for a subsequent dialysis treatment for the patient.

This invention discloses a closed-loop precise control method and system for laser-induced acoustic pressure wave (APW) in complex intravascular lesions. This method belongs to the field of laser medical technology. This application employs a physical model for APW generation coupled with a laser-plasma-liquid medium, and designs an APW simulation calculation and tunable laser control system based on this model. By adjusting parameters such as the wavelength, pulse width, and peak power density of the tunable laser, precise forward control of the generated APW intensity is achieved. Simultaneously, based on the target APW intensity required clinically, the optimal laser parameter combination can be iteratively calculated in reverse, forming a closed-loop design from "treatment target" to "laser parameters." This invention combines a laser physical model with clinical needs, realizing the quantification, predictability, and controllability of APW intensity, providing a precise and intelligent technical solution for the treatment of intravascular calcification. It can significantly simplify physician operations and improve the safety and effectiveness of treatment.

The application discloses a kind of single-cell transcriptome analysis methods and application of Crohn's disease creeping fat microenvironment, belong to the field of biological medicine technology.The method is by obtaining the single-cell and batch transcriptome data of mesenteric adipose tissue of Crohn's disease patient and healthy control, constructs relevant gene set and carries out data quality control, clustering and cell annotation;Mesenchymal stem cells are subpopulation identified, abundance analysis and function typing, combined with signal path analysis and cell communication analysis, and the key factor of regulating creeping fat microenvironment is screened out.The application first systematically analyzes the cell heterogeneity and MSC subpopulation characteristics of Crohn's disease creeping fat microenvironment, and determines the key signal path and regulating molecule, which can provide efficient and reliable technical means for the pathogenesis research, treatment target screening and creeping fat related molecule identification of Crohn's disease, and has high scientific research and clinical application value.

The application provides application of FABP4 in preparation of a preeclampsia diagnosis product and a preeclampsia treatment drug, belongs to the technical field of biotechnology, and in particular, the application provides application of a FABP4 detection reagent in preparation of a preeclampsia diagnosis product and application of a FABP4 inhibitor in preparation of a preeclampsia treatment drug, and the application proves for the first time that FABP4 can be used as a preeclampsia diagnosis marker and proves that FABP4 can be directly used as a treatment target of preeclampsia, provides a diagnosis and treatment target for diagnosis and treatment of preeclampsia, lays a solid foundation for development of a preeclampsia treatment drug, and opens up a new way for precise treatment of preeclampsia.

The application discloses application of TGM2 as a cervical cancer diagnosis, prognosis biomarker and therapeutic target. The application provides a new cervical cancer diagnosis and prognosis marker TGM2, which can clearly characterize the occurrence and development of cervical cancer; the marker presents specific high expression phenomenon in comparison with normal tissue in human clinical cervical cancer tissue; and the marker also presents high expression in human cervical cancer cell lines. Knocking down TGM2 can inhibit the proliferation and migration ability of cervical cancer cells; TGM2, as an enzyme, has high application potential as a diagnosis and treatment target. The application provides a new marker and target for the diagnosis, prognosis and treatment of cervical cancer, and can provide a new strategy and direction for the treatment of cervical cancer.

The application discloses a biomarker related to bladder cancer and application thereof, the biomarker is tRF-1:28-chrM.Ser-TGA and / or tiRNA-1:34-Glu-CTC-1-M2, which can be used for preparing a bladder cancer early high-risk patient diagnosis and / or prognosis evaluation product, and belongs to the technical field of biological medicine. The biomarker is screened through RNA sequencing, has higher sensitivity and specificity as a biomarker, and is verified through qRT-PCR and ROC curve analysis, and it is proved that tRF-1:28-chrM.Ser-TGA and tiRNA-1:34-Glu-CTC-1-M2 can excellently distinguish bladder cancer patients from normal people, and can be used as an early diagnostic biomarker and a new treatment target of bladder cancer patients, which has great clinical value and practical significance for early clinical diagnosis of bladder cancer, related treatment target evaluation and improvement of the survival rate of patients.

The application discloses application of circular RNA hsa_circ_0007895 in diagnosis and treatment of colorectal cancer and a detection reagent, and belongs to the technical field of molecular biology and tumor diagnosis and treatment. Hsa_circ_0007895 is circular RNA formed by reverse splicing of the 2-6th exon of a human EYA3 gene, is abnormally highly expressed in plasma of colorectal cancer patients, and also has a differential expression trend in tissues. The application provides clinical application of hsa_circ_0007895 as a colorectal cancer diagnosis marker, is used for auxiliary diagnosis, risk stratification and postoperative monitoring of colorectal cancer, simultaneously develops a specific detection kit, contains primers crossing reverse splicing sites, and can realize specific detection of hsa_circ_0007895. In addition, it is confirmed that hsa_circ_0007895 can be used as a colorectal cancer treatment target, and can inhibit the malignant phenotype of colorectal cancer cells by knocking down the expression. The application provides a new idea and tool for diagnosis and targeted intervention of colorectal cancer, and has potential clinical application value.

The application provides an application of YAP in preparation of a drug for preventing or treating retinal ganglion cell injury, and proves that up-regulation of YAP expression or activity can significantly reduce the retinal oxidative stress level, inhibit the neuroinflammatory response, and reduce the number of RGC death, thereby effectively protecting the nerve function. The application provides a new treatment target for diseases characterized by RGC injury, such as traumatic optic neuropathy and glaucoma, and YAP or an expression promoter thereof can be used for preparing a drug for preventing, relieving and / or treating the diseases, and has an important clinical application prospect.

This invention relates to the field of medical information technology, and provides a method for orthodontic multimodal structured integration and constraint generation, comprising: S1: receiving at least two orthodontic-related modal data of the same patient; S2: mapping candidate clinical results to a preset orthodontic semantic slot pool to generate slot-level structured records; S3: determining the primary evidence modality and secondary evidence modality from preset task-evidence modality association rules according to the orthodontic task category to which each orthodontic semantic slot belongs; S4: generating a patient fixed diagnostic baseline data object; S5: under the condition of only reading the fixed diagnostic baseline data object and not writing to the fact data layer, calling the treatment content generation module to generate at least one of candidate treatment goals, candidate treatment paths, alternatives, and risk warnings; S6: outputting machine-readable structured data and doctor-readable auxiliary reports. This solves the problems in the prior art where multimodal results cannot be uniformly organized and cross-modal conflicts cannot be adjudicated according to orthodontic task categories.

The application discloses application of isoprenyl cysteine carboxymethyltransferase as a rheumatoid arthritis treatment target in preparation of a rheumatoid arthritis treatment drug. The application finds that the expression of ICMT is down-regulated after NSUN2 is knocked out, further research on the expression level of ICMT in RA FLS finds that the mRNA and protein expression of RA FLS ICMT is obviously up-regulated, the cell migration and invasion ability is reduced after ICMT is knocked down, and the expression of MMPs such as MMP1, MMP3 and MMP9 of RA FLS is obviously inhibited. The above results show that ICMT can regulate the abnormal migration and invasion of RA FLS, and targeting ICMT can become a new means to prevent RA joint destruction. Therefore, the application provides an effective treatment target for RA, and provides a new idea for clinical treatment of RA.

The application discloses application of GPR50 in treatment of fat-related diseases, relates to the technical field of biological medicine, and specifically provides application of GPR50 as a treatment target in screening or preparation of a drug for treating fat-related diseases. The application finds that deletion of GPR50 not only promotes lipid droplet generation, but also aggravates the degree of lipid accumulation, that is, GPR50 plays an inhibitory regulatory role in adipocyte adipogenic differentiation and lipid droplet formation, and helps to maintain lipid metabolism homeostasis. Meanwhile, deletion of GPR50 makes the expression levels of various pro-inflammatory factor genes in adipocytes significantly increase, which indicates that deletion of GPR50 can enhance the inflammatory response of adipocytes after differentiation. Therefore, GPR50 can be used as a treatment target in screening or preparation of a drug for treating fat-related diseases.

The present application relates to the technical field of medical data processing, and particularly relates to a precise positioning system for incomplete skull time interference electric stimulation treatment target. The interference position analysis base model acquisition module is used for training the interference position analysis base model of the skull health user based on the graph neural network; the model selective activation module is used for selectively activating the interference position analysis base model based on the neuron nodes corresponding to the defect brain region position of the skull defect patient, and obtaining the interference position analysis selected model; the predicted interference position acquisition module is used for processing the time interference stimulation parameters and the preset individual parameters through the interference position analysis selected model, and obtaining the predicted interference position; and the time interference stimulation parameter recommendation module is used for performing the recommendation identification on the time interference stimulation parameters when the predicted interference position is consistent with the target interference position. The present application solves the problems of inaccurate positioning and difficult electrode placement caused by skull defects.

Provided is an endoscope capable of reliably illuminating a treatment tool delivered from a treatment tool delivery port and a treatment target region thereof.An endoscope includes a distal end part body that is provided on a distal end side of an insertion part and has a distal end, a proximal end, and a longitudinal axis; the treatment tool delivery port that is formed in the distal end part body and delivers the treatment tool inserted into the insertion part; an elevator that is rotatably supported in the treatment tool delivery port of the distal end part body and controls a delivery direction of the treatment tool delivered from the treatment tool delivery port; and a first illumination window that is provided on the distal end part body. The first illumination window is provided in a proximal end side region at a position shifted from the treatment tool delivery port to a proximal end side of the distal end part body in the distal end part body.

The application discloses application of CXCL12 or CXCR4 as a target point in preparation of a drug for treating a cerebral small vessel disease, and can predict the cerebral small vessel disease by detecting expression levels of the CXCL12 or the CXCR4; and further discloses application of the CXCL12 or the CXCR4 as a diagnostic marker of the cerebral small vessel disease, wherein the CXCL12 or the CXCR4 inhibitor comprises Plerixafor hydrochloride. The application discloses a new use of the CXCL12 or the CXCR4 as a cerebral small vessel disease marker and a treatment target point, and provides an important basis for clinical transformation of an inhibitor thereof.

The application of ITIH3 as a therapeutic target in the preparation of a drug for treating gastric cancer, the present application finds that ITIH3 is specifically highly expressed in the prognosis very poor gastric cancer GS (genomic stability) subtype and MSS / EMT (microsatellite stable / epithelial-mesenchymal transition) subtype through bioinformatics analysis; In vitro and in vivo functional experiments confirm that ITIH3 can drive the epithelial-mesenchymal transition (EMT) process of gastric cancer cells, significantly promote the proliferation, clonogenicity, invasion and in vivo tumorigenicity of gastric cancer cells. Based on this, the present application further screens and verifies that the known compound Kukoamine B can be used as a small molecule inhibitor targeting ITIH3, which can effectively inhibit the growth of ITIH3 highly expressed gastric cancer cells in vitro and in vivo. The present application provides a new precise treatment target and candidate drug for treating the high-invasive and high-EMT characteristic gastric cancer subtype which lacks existing means, and has good clinical application prospect.

The application belongs to the technical field of biological medicine, and discloses application of ERBB4 as a treatment target in neuroblastoma treatment. The application discloses application of a reagent for detecting ERBB4 in preparation of a product for evaluating treatment efficacy of neuroblastoma. The application proves that ERBB4 is a potential risk factor for high-risk neuroblastoma recurrence through multi-omics research and mechanism analysis of metabolic regulation network of ERBB4, and verifies the preclinical application value of the target point through a verification test, thereby providing a new target point with stable expression for precise diagnosis and treatment of refractory and recurrent neuroblastoma. Experiments prove that high expression of ERBB4 plays an inhibitory role on neuroblastoma by activating immune effect, improves the response rate of neuroblastoma to chemotherapy and immunotherapy, improves the overall treatment efficiency, has good clinical transformation value, and has important significance for the treatment of neuroblastoma.

The application provides an infrared physiotherapy cabin system and method based on animal and environment collaborative regulation, relates to the field of animal physiotherapy and intelligent monitoring and control, and comprises an animal state and cabin environment monitoring module, an infrared physiotherapy and cabin environment regulation module, an animal health assessment and curative effect assessment module, a personalized treatment and intelligent decision module, and a man-machine interaction and safety supervision module. Through multi-modal data synchronous alignment and data quality evaluation, a reliability result is formed, a health state representation is constructed under the reliability gating, and a risk level is output, infrared physiotherapy control parameters and cabin environment regulation control parameters are generated under the stage control boundary and treatment target constraint, and are executed, and online fine adjustment is performed on continuous adjustable parameters during physiotherapy, and rollback and interlock protection are performed when the risk is adjusted up or the reliability is decreased. After a cycle, curative effect is evaluated, data recording and tracing archiving are completed, and animal state and cabin environment collaborative closed-loop infrared physiotherapy regulation is realized.

A method includes receiving a) orthognathic patient data comprising information representing an initial state of a patient and b) plurality of treatment parameters that are based on a treatment goal for the patient. The method further includes generating an output state of the patient based on the initial state of the patient and the plurality of treatment parameters, calculating an objective function based on the output state of the patient and the treatment goal of the patient, and updating one or more of the treatment parameters based on the objective function.

The application discloses application of MAFF as a rheumatoid arthritis treatment target, and relates to rheumatoid arthritis. Compared with an intervention strategy of the prior art which is only directed to a single node in a downstream of an inflammation path, targeting MAFF can break the pathogenic amplification loop from an upstream key node, thereby providing a new theoretical basis and intervention strategy for realizing more fundamental treatment.

The application discloses application of a transcription factor ZNF753 in non-small cell lung cancer and belongs to the field of biological medicine. Specifically, the application relates to application of a substance for inhibiting expression or activity of the transcription factor ZNF753 in preparation of a drug for treating non-small cell lung cancer. The substance for inhibiting expression or activity of the transcription factor ZNF753 can be an shRNA targeting ZNF753. Compared with the prior art, the application provides a new treatment target for non-small cell lung cancer, solves the limitation of traditional treatment of non-small cell lung cancer by targeting downstream kinases, clarifies a molecular mechanism of ZNF753 in promoting development of non-small cell lung cancer, and lays a theoretical foundation for clinical drug development.

The application discloses application of RPL27A gene and / or RPL27A protein in preparation of a meningioma treatment drug. The application provides a new meningioma treatment target, and the RPL27A has a significant anti-meningioma function, can inhibit occurrence, development and metastasis of meningioma, and has wide clinical application value for development of a new meningioma diagnosis marker and a treatment drug.